EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review

Antzeko izenburuak

• Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
  nork: Igor Makhlin, et al.
  Argitaratua: (2019-11-01)
• A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
  nork: K. K. Laktionov, et al.
  Argitaratua: (2019-06-01)
• Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
  nork: Xu H, et al.
  Argitaratua: (2019-07-01)
• Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
  nork: Keunchil Park, MD, PhD, et al.
  Argitaratua: (2021-09-01)
• Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy
  nork: Priyanka S. Waghmare, et al.
  Argitaratua: (2024-07-01)